Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis

Kazuteru Ohashi, Tokiko Nagamura-Inoue, Fumitaka Nagamura, Arinobu Tojo, Kouichi Miyamura, Takehiko Mori, Mineo Kurokawa, Shuichi Taniguchi, Jun Ishikawa, Yasuo Morishima, Yoshiko Atsuta, Hisashi Sakamaki

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We retrospectively compared transplant outcomes for related bone marrow transplantation (rBMT), related peripheral blood stem cell transplantation (rPBSCT), unrelated bone marrow transplantation (uBMT), and unrelated cord blood transplantation (CBT) in 1,062 patients with chronic myeloid leukemia (CML) aged 20 years or over between January 1, 2000 and December 31, 2009 in Japan. The disease status was as follows: chronic phase 1 (CP1, n = 531), CP 2 or later including accelerated phase (CP2-AP, n = 342) and blastic crisis (BC, n = 189). Graft sources (GS) were rBMT (n = 205), uBMT (n = 507), rPBSCT (n = 226) or CBT (n = 124). In multivariate analysis in CP1, lower overall survival (OS) (relative risk [RR]: 6.01, 95 % confidence interval [CI]: 1.20-29.97, P = 0.029) and leukemia-free survival (LFS) (RR: 4.26, 95 % CI: 1.24-14.62, P = 0.021) were observed in uBMT compared with those in rBMT. For patients in the advanced phase of CML beyond CP1, GS had no significant impact on OS or LFS. Our results support the use of rBMT for adults with CML in CP1, but in contrast to previous reports, the superiority of rPBSCT in advanced stage of CML was not confirmed in our cohorts.

Original languageEnglish
Pages (from-to)296-306
Number of pages11
JournalInternational Journal of Hematology
Volume100
Issue number3
DOIs
Publication statusPublished - 2014 Sep 1

Fingerprint

Hematopoietic Stem Cell Transplantation
Cell Transplantation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone Marrow Transplantation
Protein-Tyrosine Kinases
Transplants
Peripheral Blood Stem Cell Transplantation
Survival
Fetal Blood
Leukemia
Transplantation
Confidence Intervals
Leukemia, Myeloid, Chronic Phase
Japan
Multivariate Analysis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors : a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis. / Ohashi, Kazuteru; Nagamura-Inoue, Tokiko; Nagamura, Fumitaka; Tojo, Arinobu; Miyamura, Kouichi; Mori, Takehiko; Kurokawa, Mineo; Taniguchi, Shuichi; Ishikawa, Jun; Morishima, Yasuo; Atsuta, Yoshiko; Sakamaki, Hisashi.

In: International Journal of Hematology, Vol. 100, No. 3, 01.09.2014, p. 296-306.

Research output: Contribution to journalArticle

Ohashi, Kazuteru ; Nagamura-Inoue, Tokiko ; Nagamura, Fumitaka ; Tojo, Arinobu ; Miyamura, Kouichi ; Mori, Takehiko ; Kurokawa, Mineo ; Taniguchi, Shuichi ; Ishikawa, Jun ; Morishima, Yasuo ; Atsuta, Yoshiko ; Sakamaki, Hisashi. / Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors : a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis. In: International Journal of Hematology. 2014 ; Vol. 100, No. 3. pp. 296-306.
@article{4e62819ccf844f51ab970cacf3753509,
title = "Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis",
abstract = "We retrospectively compared transplant outcomes for related bone marrow transplantation (rBMT), related peripheral blood stem cell transplantation (rPBSCT), unrelated bone marrow transplantation (uBMT), and unrelated cord blood transplantation (CBT) in 1,062 patients with chronic myeloid leukemia (CML) aged 20 years or over between January 1, 2000 and December 31, 2009 in Japan. The disease status was as follows: chronic phase 1 (CP1, n = 531), CP 2 or later including accelerated phase (CP2-AP, n = 342) and blastic crisis (BC, n = 189). Graft sources (GS) were rBMT (n = 205), uBMT (n = 507), rPBSCT (n = 226) or CBT (n = 124). In multivariate analysis in CP1, lower overall survival (OS) (relative risk [RR]: 6.01, 95 {\%} confidence interval [CI]: 1.20-29.97, P = 0.029) and leukemia-free survival (LFS) (RR: 4.26, 95 {\%} CI: 1.24-14.62, P = 0.021) were observed in uBMT compared with those in rBMT. For patients in the advanced phase of CML beyond CP1, GS had no significant impact on OS or LFS. Our results support the use of rBMT for adults with CML in CP1, but in contrast to previous reports, the superiority of rPBSCT in advanced stage of CML was not confirmed in our cohorts.",
author = "Kazuteru Ohashi and Tokiko Nagamura-Inoue and Fumitaka Nagamura and Arinobu Tojo and Kouichi Miyamura and Takehiko Mori and Mineo Kurokawa and Shuichi Taniguchi and Jun Ishikawa and Yasuo Morishima and Yoshiko Atsuta and Hisashi Sakamaki",
year = "2014",
month = "9",
day = "1",
doi = "10.1007/s12185-014-1632-9",
language = "English",
volume = "100",
pages = "296--306",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

T2 - a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis

AU - Ohashi, Kazuteru

AU - Nagamura-Inoue, Tokiko

AU - Nagamura, Fumitaka

AU - Tojo, Arinobu

AU - Miyamura, Kouichi

AU - Mori, Takehiko

AU - Kurokawa, Mineo

AU - Taniguchi, Shuichi

AU - Ishikawa, Jun

AU - Morishima, Yasuo

AU - Atsuta, Yoshiko

AU - Sakamaki, Hisashi

PY - 2014/9/1

Y1 - 2014/9/1

N2 - We retrospectively compared transplant outcomes for related bone marrow transplantation (rBMT), related peripheral blood stem cell transplantation (rPBSCT), unrelated bone marrow transplantation (uBMT), and unrelated cord blood transplantation (CBT) in 1,062 patients with chronic myeloid leukemia (CML) aged 20 years or over between January 1, 2000 and December 31, 2009 in Japan. The disease status was as follows: chronic phase 1 (CP1, n = 531), CP 2 or later including accelerated phase (CP2-AP, n = 342) and blastic crisis (BC, n = 189). Graft sources (GS) were rBMT (n = 205), uBMT (n = 507), rPBSCT (n = 226) or CBT (n = 124). In multivariate analysis in CP1, lower overall survival (OS) (relative risk [RR]: 6.01, 95 % confidence interval [CI]: 1.20-29.97, P = 0.029) and leukemia-free survival (LFS) (RR: 4.26, 95 % CI: 1.24-14.62, P = 0.021) were observed in uBMT compared with those in rBMT. For patients in the advanced phase of CML beyond CP1, GS had no significant impact on OS or LFS. Our results support the use of rBMT for adults with CML in CP1, but in contrast to previous reports, the superiority of rPBSCT in advanced stage of CML was not confirmed in our cohorts.

AB - We retrospectively compared transplant outcomes for related bone marrow transplantation (rBMT), related peripheral blood stem cell transplantation (rPBSCT), unrelated bone marrow transplantation (uBMT), and unrelated cord blood transplantation (CBT) in 1,062 patients with chronic myeloid leukemia (CML) aged 20 years or over between January 1, 2000 and December 31, 2009 in Japan. The disease status was as follows: chronic phase 1 (CP1, n = 531), CP 2 or later including accelerated phase (CP2-AP, n = 342) and blastic crisis (BC, n = 189). Graft sources (GS) were rBMT (n = 205), uBMT (n = 507), rPBSCT (n = 226) or CBT (n = 124). In multivariate analysis in CP1, lower overall survival (OS) (relative risk [RR]: 6.01, 95 % confidence interval [CI]: 1.20-29.97, P = 0.029) and leukemia-free survival (LFS) (RR: 4.26, 95 % CI: 1.24-14.62, P = 0.021) were observed in uBMT compared with those in rBMT. For patients in the advanced phase of CML beyond CP1, GS had no significant impact on OS or LFS. Our results support the use of rBMT for adults with CML in CP1, but in contrast to previous reports, the superiority of rPBSCT in advanced stage of CML was not confirmed in our cohorts.

UR - http://www.scopus.com/inward/record.url?scp=84927171026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927171026&partnerID=8YFLogxK

U2 - 10.1007/s12185-014-1632-9

DO - 10.1007/s12185-014-1632-9

M3 - Article

VL - 100

SP - 296

EP - 306

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -